Therapeutic agents
The invention provides well-defined compounds that are either EP 2 agonists, EP 4 agonists, or mixed EP 2 /EP 4 agonist. The compounds are useful for treating a variety of pathological conditions associated with activity of the EP 2 and/or EP 4 receptors.
1. A compound having the structure:
wherein:
Ar is aryl, heteroaryl, substituted aryl, or substituted heteroaryl, wherein substituents are selected from alkyl, alkenyl, alkynyl, hydroxyalkyl, hydroxyl, alkoxy, halogen, —CN, —CF 3 , —C(O)R 1 , —C(O)OR 1 , —C(O)CF 3 , —SO 2 N(R 1 ) 2 , —SO 2 NH 2 , or —NO 2 ;
L is C 1 -C 6 alkylene;
A is arylene or heteroarylene;
E is —CO 2 R 1 , —CH 2 OR 1 , —C(O)N(R 1 ) 2 , or tetrazol-5-yl;
each R 1 is independently H, C 1 -C 6 alkyl, phenyl, or biphenyl; and
n is 0 or 1;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein Ar is substituted or unsubstituted phenyl or naphthyl.
3. The compound of claim 1 , wherein the substituents are halogen, alkoxy, or —CF 3 .
4. The compound of claim 1 , wherein L is C 1 -C 3 alkylene.
5. The compound of claim 1 , wherein L is methylene.
6. The compound of claim 1 , wherein A is phenylene or thiophenylene.
7. The compound of claim 1 , wherein E is —CO 2 R 1 .
8. The compound of claim 7 , wherein R 1 is H or C 1 -C 6 alkyl.
9. A pharmaceutical composition comprising at least one compound according to claim 1 , and a pharmaceutically acceptable carrier therefor.
10. The compound of claim 1 selected from the group consisting of:
11. A compound having the structure:
or a pharmaceutically acceptable salt thereof.